Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

870
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
870
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

807
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
807
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

806
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
806
Huntington Disease l: Introduction01:21

Huntington Disease l: Introduction

6
Huntington disease or HD is a progressive, fatal neurodegenerative disorder inherited in an autosomal dominant pattern.PathophysiologyIt is caused by expansion of the CAG trinucleotide repeat in the HTT gene on chromosome 4 (4p16.3), producing an abnormal huntingtin protein with an expanded polyglutamine tract. This misfolded protein disrupts cellular function, leading to neuronal death. Normal alleles have ≤26 repeats, 27–35 are intermediate (risk of expansion), 36–39 show...
6
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

924
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
924
Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

3
Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
3

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

VGLL3-Rearranged Spindle Cell Rhabdomyoblastic Tumor: A Clinicopathologic and Molecular Genetic Study of 18 Cases With Consistently Indolent Behavior.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc·2026
Same author

Are We Moving Toward Curative Approaches in Chronic Lymphocytic Leukemia?

Acta medica (Hradec Kralove)·2026
Same author

Repression of miR-29 via MYC leads to increased CD40 signaling in transformed follicular lymphoma.

Leukemia·2026
Same author

Chronic Silicone Embolism Syndrome.

International journal of surgical pathology·2026
Same author

Utility of HoxB13 in differential diagnosis of female genital tract lesions with putative prostatic differentiation.

Virchows Archiv : an international journal of pathology·2025
Same author

Field size as a determinant of common vole population density.

Pest management science·2025
Same journal

EBV-associated plasmacytic variant of Castleman disease: more than a decade-long diagnostic odyssey - a case report.

Ceskoslovenska patologie·2026
Same journal

Castleman-Like Lymphadenopathy in a Patient with Mixed Connective Tissue Disease: A Case Report and Review of the Literature.

Ceskoslovenska patologie·2026
Same journal

Targeted gene expression profiling as a tool for diagnostic cell-of-origin determination and prognostic stratification in diffuse large B-cell lymphoma.

Ceskoslovenska patologie·2026
Same journal

The advantages and limitations of the new FIGO 2023 staging system for endometrial carcinoma from the perspective of the clinician and pathologist.

Ceskoslovenska patologie·2026
Same journal

Testing Claudin 18.2 Expression in Gastric and Gastroesophageal Junction Adenocarcinoma: Current Status and Near‑Future Outlook.

Ceskoslovenska patologie·2026
Same journal

Current methods in multiplex immunohistochemistry for formalin-fixed tissue samples.

Ceskoslovenska patologie·2026
See all related articles

Related Experiment Video

Updated: Apr 19, 2026

Fingerprinting Cardiolipin in Leukocytes by Mass Spectrometry for a Rapid Diagnosis of Barth Syndrome
06:48

Fingerprinting Cardiolipin in Leukocytes by Mass Spectrometry for a Rapid Diagnosis of Barth Syndrome

Published on: March 23, 2022

2.8K

Castleman disease - one name, many faces.

Kateřina Kamarádová, Václav Stejskal, Dominika Écsiová

    Ceskoslovenska Patologie
    |April 17, 2026
    PubMed
    Summary
    This summary is machine-generated.

    Castleman disease is a lymph node disorder with varied causes and presentations. Diagnosis and treatment depend on subtype, ranging from surgery for unicentric forms to complex therapies for multicentric Castleman disease.

    Keywords:
    Castleman diseaseHHV-8-positive multicentric Castleman diseasePOEMS syndromeTAFRO syndromehyalinne-vascular morphologyhypervascular morphologyidiopathic multicentric Castleman diseaseplasma cell typeunicentric Castleman disease

    More Related Videos

    Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
    03:45

    Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

    Published on: August 8, 2022

    4.4K
    A Metadata Extraction Approach for Clinical Case Reports to Enable Advanced Understanding of Biomedical Concepts
    07:50

    A Metadata Extraction Approach for Clinical Case Reports to Enable Advanced Understanding of Biomedical Concepts

    Published on: September 20, 2018

    16.7K

    Related Experiment Videos

    Last Updated: Apr 19, 2026

    Fingerprinting Cardiolipin in Leukocytes by Mass Spectrometry for a Rapid Diagnosis of Barth Syndrome
    06:48

    Fingerprinting Cardiolipin in Leukocytes by Mass Spectrometry for a Rapid Diagnosis of Barth Syndrome

    Published on: March 23, 2022

    2.8K
    Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
    03:45

    Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

    Published on: August 8, 2022

    4.4K
    A Metadata Extraction Approach for Clinical Case Reports to Enable Advanced Understanding of Biomedical Concepts
    07:50

    A Metadata Extraction Approach for Clinical Case Reports to Enable Advanced Understanding of Biomedical Concepts

    Published on: September 20, 2018

    16.7K

    Area of Science:

    • Hematology
    • Pathology
    • Oncology

    Background:

    • Castleman disease (CD) is a heterogeneous group of lymphoproliferative disorders.
    • Morphologically, CD is classified into hyaline-vascular, plasmacytic, and mixed types.
    • Diagnosis requires integrating clinical criteria with pathological findings.

    Purpose of the Study:

    • To provide a comprehensive overview of Castleman disease.
    • To describe the morphological changes and clinical characteristics of CD subtypes.
    • To highlight the diagnostic and therapeutic complexities of CD.

    Main Methods:

    • Review of current literature and clinical guidelines.
    • Analysis of morphological classifications (hyaline-vascular, plasmacytic, mixed).
    • Correlation of clinical presentations with disease subtypes (unicentric, multicentric).

    Main Results:

    • Unicentric CD typically involves a single lymph node, often curable by surgery.
    • Multicentric CD affects multiple lymph nodes, presenting with systemic symptoms.
    • Multicentric CD subtypes include idiopathic (TAFRO syndrome, plasmacytic lymphadenopathy) and HHV-8/POEMS-associated forms.

    Conclusions:

    • Castleman disease diagnosis and management are complex, requiring multidisciplinary collaboration.
    • Treatment strategies for multicentric CD are etiological and may involve biological agents, chemotherapy, or IL-6 inhibition.
    • Accurate subtyping is crucial for effective treatment of Castleman disease.